Composition
- Active ingredients
- CABOZANTINIB 13MG
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- CABOZANTINIB 26MG · TabletNDA220258-002 · Prescription
- CABOZANTINIB 39MG · TabletNDA220258-003 · Prescription
- CABOZANTINIB 13MG · TabletThis page
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA220258.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Resniben
- Active substance
- cabozantinib
- Route
- Oral
- Dosage form
- Tablet
- Applicant
- Azurity
- Status
- Prescription
- FDA approval
- 24 Oct 2025
- Application
- NDA220258-001